-
Company Insights
Innovation and Patenting activity of Accell Group N.V. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Accell Group N.V. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
Frictionless Commerce – Thematic Intelligence
Frictionless Commerce Thematic Report Overview At present, consumers demand instant gratification, and frictionless commerce aims to provide it. Frictionless commerce was pioneered by Amazon. It uses technology to identify the shopper, recognize their chosen objects, and bill them after they leave the store. The Frictionless Commerce thematic intelligence report provides an overview of the current landscape, as well as key players making a mark within it. The report provides an industry-specific analysis based on GlobalData databases and surveys, along with...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Head And Neck Squamous Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Cervical Cancer Drug Details: TOS-358 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Endometrial Cancer Drug Details: TOS-358 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Gastric Cancer Drug Details: TOS-358 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Solid Tumor Drug Details: TOS-358 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Non-Small Cell Lung Cancer Drug Details: TOS-358 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Metastatic Colorectal Cancer Drug Details: TOS-358 is under development...